BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

BXPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

BXPHARMA 26-Oct-2017

The Board of Directors has recommended 12.50% cash dividend for the year ended on June 30, 2017. Date of AGM: 23.12.2017, Time: 10:00 AM, Venue: Beximco Industrial Park, Sarabo, Kashimpur, Gazipur. Record Date: 15.11.2017. (cont.)

BXPHARMA 19-Oct-2017

As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 25, 2017 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2017.

BXPHARMA 08-Oct-2017

(continuation news of BXPHARMA): with a local manufacturing facility at Tongi, Gazipur. They also have a long-term manufacturing and marketing collaboration with Merck Sharp & Dohme (MSD). According to the Quintiles IMS Q2 2017 data of the retail pharma market in Bangladesh, Nuvista Pharma currently ranks as the 21st largest supplier to the market by volume. (end)

BXPHARMA 08-Oct-2017

(continuation news of BXPHARMA): It is expected that the Proposed Acquisition will be completed by the end of December 2017 and will, if completed, accelerate revenue growth and improve the earning potential for Beximco Pharma. The Company has further informed that Nuvista Pharma Ltd, formerly Organon (Bangladesh) Ltd., was a subsidiary of Netherlands based Organon International. It was sold out to the current Bangladeshi Management in 2006. The Company has been operating in Bangladesh since 1964 (cont. 2)

BXPHARMA 08-Oct-2017

The Company has informed that the Board of Directors of the Company has decided to enter into a non-binding Memorandum of Understanding (MOU) under which Beximco Pharma may acquire a majority shareholding (85.22%) in Nuvista Pharma Ltd. a leading pharma Company in Bangladesh specializing in hormones and steroid drugs (the proposed acquisition). The proposed acquisition remains subject to due diligence and negotiation and completion of a definitive Sale and Purchase Agreement. (cont. 1)

BXPHARMA 11-Jun-2017

Credit Rating Information and Services Limited (CRISL) has rated the Company as "AA+" in the long term and "ST-1" in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2016, unaudited financials up to March 31, 2017 and other relevant quantitative as well as qualitative information up to the date of rating declaration.

BXPHARMA 27-Apr-2017

(Q3 Un-audited): EPS was Tk. 1.29 for January-March, 2017 as against Tk. 1.06 for January-March, 2016; EPS was Tk. 4.03 for July, 2016-March, 2017 as against Tk. 3.39 for July, 2015-March, 2016. NOCFPS was Tk. 4.37 for July, 2016-March, 2017 as against Tk. 4.77 for July, 2015-March, 2016. NAV per share was Tk. 60.36 as of March 31, 2017 and Tk. 59.24 as of March 31, 2016.

BXPHARMA 23-Apr-2017

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 27, 2017 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2017.

BXPHARMA 06-Apr-2017

In response to a DSE query dated April 05, 2017, the Company has informed that there is no undisclosed price sensitive information of the Company for recent unusual price hike.

BXPHARMA 26-Jan-2017

(Q2 Un-audited): EPS was Tk. 1.47 for October-December, 2016 as against Tk. 1.29 for October-December, 2015; EPS was Tk. 2.74 for July-December, 2016 as against Tk. 2.33 for July-December, 2015. NOCFPS was Tk. 2.56 for July-December, 2016 as against Tk. 3.28 for July-December, 2015. NAV per share was Tk. 59.07 as of December 31, 2016 and Tk. 58.20 as of December 31, 2015.

Previous Next page